All In Biotech

Drug Trial Radar · NCT04802759

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 316 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

316

Planned (sponsor's estimate)

Start

Jun 22, 2021

Primary completion

May 30, 2029

Study completion May 30, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the patient population. Cohort 1 will focus on participants with inoperable, locally advanced or metastatic, estrogen receptor-positive (ER+), HER2-negative breast cancer who had disease progression during or following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; e.g., palbociclib, ribociclib, abemaciclib) in the first- or second-line setting. Cohort 2 will focus on inoperable, locally advanced or metastatic, ER+, HER2-positive breast cancer with previous progression to standard-of-care anti-HER2 therapies, of which one was a trastuzumab-and-taxane-based systemic therapy (including in the early setting if recurrence occurred within 6 months of finishing adjuvant therapy) and one was a HER2-targeting antibody-drug conjugate (ADC; e.g., ado-trastuzumab emtansine or trastuzumab-deruxtecan) or a HER2-targeting tyrosine kinase inhibitor (TKI; e.g., tucatinib, lapatinib, pyrotinib, or neratinib). Cohort 3 will focus on inoperable, locally advanced or metastatic, ER+, HER2-negative, PIK3CA-mutated breast cancer with resistance to adjuvant endocrine therapy.

Conditions

  • Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

Interventions

  • GiredestrantDrug

    30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

  • AbemaciclibDrug

    150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

  • IpatasertibDrug

    400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression

  • InavolisibDrug

    9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression

  • RibociclibDrug

    600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression

  • EverolimusDrug

    10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression

  • SamuraciclibDrug

    360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression

  • PH FDC SCDrug

    On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.

  • PalbociclibDrug

    125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression

  • AtezolizumabDrug

    840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Objective Response, Defined as a Complete or Partial Response, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)Time frame: From Baseline until disease progression (up to 6 years)
  2. Number of Participants with Adverse Events, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0)Time frame: From Baseline until 30 days after the last dose of study drug (up to 6 years)

Locations

32 sites in 5 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • City of Hope - Orange County Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • University of California, San Francisco (UCSF)

    San Francisco, California · Recruiting

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Santa Monica, California · Recruiting

  • Stanford Cancer Institute (SCI)

    Stanford, California · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Regional Cancer Care Associates LLC (RCCA) - Freehold Location

    Freehold, New Jersey · Withdrawn

  • Regional Cancer Care Associates LLC ? Howell Division

    Howell Township, New Jersey · Withdrawn

  • Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh Cancer Institute

    Pittsburgh, Pennsylvania · Withdrawn

  • West Cancer Center

    Germantown, Tennessee · Recruiting

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia · Recruiting

  • Peninsula Health-Frankston Hospital

    Frankston, Victoria, Australia · Recruiting

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Linear Clinical Research Limited

    Nedlands, Western Australia, Australia · Recruiting

  • Rambam Medical Center

    Haifa, Israel · Recruiting

  • Hadassah Ein Karem Hospital

    Jerusalem, Israel · Recruiting

  • Rabin MC

    Petah Tikva, Israel · Recruiting

  • The Chaim Sheba Medical Center

    Ramat Gan, Israel · Recruiting

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel · Recruiting

  • Assuta Medical Centers

    Tel Aviv, Israel · Recruiting

  • Shaare Zedek Medical Center

    Jerusalem, Jerusalem, Israel · Recruiting

  • National Cancer Center

    Goyang-si, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

  • Hospital Universitario Vall d Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain · Recruiting

  • Centro Integral Oncológico Clara Campal Ensayos Clínicos START

    Madrid, Spain · Recruiting

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.